Charles River Laboratories International, Inc. (CRL) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in Wilmington, MA, United States. Der aktuelle CEO ist James C. Foster.
CRL hat IPO-Datum 2000-06-23, 18,700 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $8.83B.
Charles River Laboratories International, Inc. is a leading non-clinical contract research organization founded in 1947 and headquartered in Wilmington, Massachusetts. The company provides comprehensive drug discovery, non-clinical development, and safety testing services to pharmaceutical and biotechnology clients across the United States, Europe, Canada, Asia Pacific, and internationally. Operating through three main segments—Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions—Charles River supplies research animal models, conducts early-stage drug discovery and toxicology testing, and provides quality control and specialized testing services for pharmaceuticals and biologics. The company's offerings span the entire pre-clinical development pipeline, from target identification through safety assessment, as well as avian vaccine services and contract vivarium operations.
